Co-Diagnostics vs Femasys
CODX and FEMY side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CODX and FEMY compare
Femasys is the larger company, worth 7.2 times as much as Co-Diagnostics ($12.6M against $1.7M).
Co-Diagnostics grew revenue faster over the last twelve months (69.1% versus 21.9% for Femasys).
Femasys keeps more of each dollar of sales as profit, with a net margin of −512% compared with −5528% at Co-Diagnostics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CODX | FEMY |
|---|---|---|
| Size and price | ||
| Market cap | $1.7M | $12.6M |
| Share price | $0.278 | $1.50 |
| Change, 1 year | −97.6% | −92.8% |
| Change, 5 years | −99.9% | −98.5% |
| Beta (5Y) | 1.76 | 0.44 |
| Employees | 115 | 51 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 1 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.0× (better) | 5.5× |
| P/B | 0.2× (better) | 3.1× |
| FCF yield | −1565% | −144% (better) |
| Fair value | – | $1.79 |
| Margin of safety | – | 16.3% |
| Growth | ||
| Revenue growth (TTM) | 69.1% (better) | 21.9% |
| Revenue growth, 5Y average | −61.6% | 17.2% (better) |
| Profitability | ||
| Gross margin | 20.3% | 60.9% (better) |
| Operating margin | −5614% | −764% (better) |
| Net margin | −5528% | −512% (better) |
| FCF margin | −3166% | −786% (better) |
| Return on equity | −195% (better) | −425% |
| Return on invested capital | −208% (better) | −3165% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −13.5× |
| Current ratio | 0.77 | 2.14 (better) |
| Altman Z-score | −23.29 | −20.21 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 9.5% | 24.7% |
| Held by insiders | 14.7% | 86.0% |
| Insider net buying, 12 months | – | $134K |
| Short interest, % of float | 18.4% | 4.2% |
Go deeper
- CODX stock overview
- CODX income statement
- CODX valuation and score
- FEMY stock overview
- FEMY income statement
- FEMY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.